These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is there a difference between leads and drugs? A historical perspective. Oprea TI; Davis AM; Teague SJ; Leeson PD J Chem Inf Comput Sci; 2001; 41(5):1308-15. PubMed ID: 11604031 [TBL] [Abstract][Full Text] [Related]
4. Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. Matter H J Med Chem; 1997 Apr; 40(8):1219-29. PubMed ID: 9111296 [TBL] [Abstract][Full Text] [Related]
6. Chemical substructures in drug discovery. Merlot C; Domine D; Cleva C; Church DJ Drug Discov Today; 2003 Jul; 8(13):594-602. PubMed ID: 12850335 [TBL] [Abstract][Full Text] [Related]
7. Similarity measures for rational set selection and analysis of combinatorial libraries: the Diverse Property-Derived (DPD) approach. Lewis RA; Mason JS; McLay IM J Chem Inf Comput Sci; 1997; 37(3):599-614. PubMed ID: 9177003 [TBL] [Abstract][Full Text] [Related]
8. Virtual screening of virtual libraries. Green DV Prog Med Chem; 2003; 41():61-97. PubMed ID: 12774691 [TBL] [Abstract][Full Text] [Related]
9. Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Kéri G; Székelyhidi Z; Bánhegyi P; Varga Z; Hegymegi-Barakonyi B; Szántai-Kis C; Hafenbradl D; Klebl B; Muller G; Ullrich A; Erös D; Horváth Z; Greff Z; Marosfalvi J; Pató J; Szabadkai I; Szilágyi I; Szegedi Z; Varga I; Wáczek F; Orfi L Assay Drug Dev Technol; 2005 Oct; 3(5):543-51. PubMed ID: 16305311 [TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design: combinatorial chemistry and molecular modeling. Kirkpatrick DL; Watson S; Ulhaq S Comb Chem High Throughput Screen; 1999 Aug; 2(4):211-21. PubMed ID: 10469881 [TBL] [Abstract][Full Text] [Related]
12. Molecular diversity management strategies for building and enhancement of diverse and focused lead discovery compound screening collections. Schuffenhauer A; Popov M; Schopfer U; Acklin P; Stanek J; Jacoby E Comb Chem High Throughput Screen; 2004 Dec; 7(8):771-81. PubMed ID: 15578939 [TBL] [Abstract][Full Text] [Related]
13. Organic chemistry in drug discovery. MacCoss M; Baillie TA Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494 [TBL] [Abstract][Full Text] [Related]
14. Application and utilization of chemoinformatics tools in lead generation and optimization. Fotouhi N; Gillespie P; Goodnow RA; So SS; Han Y; Babiss LE Comb Chem High Throughput Screen; 2006 Feb; 9(2):95-102. PubMed ID: 16475967 [TBL] [Abstract][Full Text] [Related]
15. Informative library design as an efficient strategy to identify and optimize leads: application to cyclin-dependent kinase 2 antagonists. Bradley EK; Miller JL; Saiah E; Grootenhuis PD J Med Chem; 2003 Sep; 46(20):4360-4. PubMed ID: 13678414 [TBL] [Abstract][Full Text] [Related]
16. Novel technologies for virtual screening. Lengauer T; Lemmen C; Rarey M; Zimmermann M Drug Discov Today; 2004 Jan; 9(1):27-34. PubMed ID: 14761803 [TBL] [Abstract][Full Text] [Related]
17. Statistical design and application to combinatorial chemistry. Rose S Drug Discov Today; 2002 Jan; 7(2):133-8. PubMed ID: 11790624 [TBL] [Abstract][Full Text] [Related]
18. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery. Fink T; Reymond JL J Chem Inf Model; 2007; 47(2):342-53. PubMed ID: 17260980 [TBL] [Abstract][Full Text] [Related]
19. Virtual screening in structure-based drug discovery. Barril X; Hubbard RE; Morley SD Mini Rev Med Chem; 2004 Sep; 4(7):779-91. PubMed ID: 15379645 [TBL] [Abstract][Full Text] [Related]